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There has been an increase in lung transplantation in the USA. Lung allocation is guided by the lung allocation score (LAS), which
takes into account one measure of exercise capacity, the 6-minute walk test (6MWT). There is a paucity of data regarding the role
and value of cardiopulmonary stress test (CPET) in the evaluation of lung transplant recipients while on the transplant waiting list
and after lung transplantation. While clearly there is a need for further prospective investigation, the available literature strongly
suggests a potential role for CPET in the setting of lung transplant.
1.Introduction
1.1. Lung Transplantation in the United States. There are
approximately 1,700 patients listed for and awaiting lung
transplantation in the United States [1]. Patients with
underlying idiopathic pulmonary ﬁbrosis (IPF), chronic
obstructive pulmonary disease (COPD), cystic ﬁbrosis,
alpha-1-antitrypsin deﬁciency, and pulmonary hypertension
comprise the majority of those awaiting transplant [2].
Since the ﬁrst successful human lung transplant in 1983
[3], there have been signiﬁcant eﬀorts to improve morbidity
and mortality associated with the procedure, particularly as
thenumberofannuallungtransplantscontinuestorisefrom
837 lung transplants in 1998 to 1,458 in 2007 [4]. One-year
survival rates have modestly improved from 73.4% to 80.4%
over that time, yet they lag behind those of other solid organ
transplant recipients [4].
Donor lungs in the United States are allocated for
use by the lung allocation score (LAS) system, which
was instituted in May 2005, in an eﬀort to reduce time
and mortality on the transplant waitlist. LAS takes into
account a number of factors (Table 1), including diagnosis,
functional status, presence of diabetes, assisted ventilation,
amount of supplemental oxygen, percent predicted forced
vital capacity (FVC), systolic and mean pulmonary artery
pressures, mean pulmonary capillary wedge pressure, pCO2
levels, six-minute walk distance, and serum creatinine [5, 6].
As recently reviewed by Eberlein et al., the LAS score places
twice as much weight on the waitlist urgency measure, which
is an estimate of the number of days expected to live on the
waitlist, as opposed to the posttransplant survival measure,
which estimates the number of days expected to live in
the ﬁrst year after transplant [7, 8]. The LAS system has
met its initial goals of decreasing mortality while on the
waitlist for transplant, as well as making lung transplant
an option for those at greatest need. However, there has
been no clear posttransplant beneﬁt in terms of changes in
morbidityormortality,thoughlonger-termdataarepending
[2, 9]. Further, the usage of the LAS resulted in increased
use of resources, morbidity, and mortality in the subgroup
of patients with very high LAS [9]. Further insight into
other parameters, beyond those in the LAS score, and how
they could predict posttransplant outcomes are therefore
absolutely necessary to guide future improvements in the
ﬁeld of lung transplantation medicine.
The role of exercise testing in decisions surrounding
appropriateness of listing patients, as well as counsel-
ing those undergoing transplant regarding life expectancy,2 Pulmonary Medicine
Table 1: Components of the Lung Allocation Score.
Date of birth
Height
Weight
Lung diagnosis
Functional status
Performs activities of daily living
Some assistance
Total assistance
No assistance
Diabetes
Dependency unknown
Not diabetic
Insulin dependent
Not insulin dependent
Mechanical ventilation
BiPAP
CPAP
Continuous mechanical
Intermittent mechanical
No assisted ventilation
Supplemental O2 requirements
At rest
At night
With exercise
Not needed
Amount (liters)FiO2 (%)
Forced vital capacity (%predicted)
Pulmonary artery systolic pressure (mmHg)
Mean pulmonary artery pressure
Pulmonary capillary wedge pressure
Current pCO2
Highest pCO2
Lowest pCO2
Change in pCO2 (%)
Six minute walk distance (feet)
Serum creatinine (mg/dL)
performance status, and posttransplant outcomes, has not
yet been fully explored. Exercise testing could provide very
useful information that may not be otherwise captured by
the LAS.
We performed a National Library of Medicine (Pubmed)
search of the English language literature using the following
queries “lung transplantation” and “exercise” or “cardiopul-
monary stress testing” or “six-minute walk test.” Additional
search words were later used for speciﬁc topics (e.g., “lung
transplantation” and “anemia” or “myopathy”). Manuscripts
were included if directly addressed the subject of this
review and oﬀered diﬀering points of view or additional
explanations.
1.2. Six-Minute Walk Test. The LAS takes into account six
minute walk test (6-MWT) performance, one measurement
of exercise capacity. The 6-MWT has been used in a
number of disease states, including conditions for which
patients undergo lung transplantation, such as COPD or
IPF, to assess functional status and therapeutic response
and deﬁne prognosis [18, 19]. One of the ﬁrst evaluations
of the performance of 6-MWT as an assessment in those
undergoing lung transplantation was completed in the
late 1990s [20]. Results of this retrospective study of 145
patients demonstrated that a pretransplant 6-minute walk
distance of less than 400 meters predicted mortality with a
sensitivity, speciﬁcity, positive predictive value, and negative
predictive value of 0.8, 0.27, 0.27, and 0.91, respectively.
The authors’ conclusion was that the 6-MWT could be
useful as a tool to help assess the timing of listing for
lung transplantation. In addition, a subsequent retrospective
study of 454 patients demonstrated that 6-MWT results—
both distance but also presence of desaturation—could be
independently associated with mortality for IPF patients
awaiting transplant, and, importantly, the test performance
was a better predictor of 6-month mortality than spirometry
[21].Thisdemonstratedtherelevanceofmeasuresofexercise
capacity, beyond the data provided by standard pulmonary
function tests.
DespiteitsincorporationintheLAS,untilrecently,the6-
MWT has not been evaluated in lung transplant recipients.
In their retrospective chart review of 49 patients who had
completed 6-MWT six months following transplant, Seoane
and colleagues deﬁned normative values for this population
and assessed whether test performance predicted mortality
[22]. At the 6-month mark, distance walked on the 6-MWT
had a normal distribution, with a mean (±SD) of 426 ±
84.5m (range 240–711m). At 12 months, for the patients in
whom data was available for both 6 months and 12 months,
a signiﬁcant improvement from 348 ± 15m to 478 ± 14m
was seen (P = .0001), with 77% of patients demonstrating
an improved walk distance. Despite these improvements, 6-
month performance was not a predictor of survival (OR =
1.002).
To date and to our knowledge, there have not been any
studies comparing pre- and post-transplant 6-MWT, so it is
not known how pretransplant 6-MWT performance relates
to posttransplant functional status and whether there is
any signiﬁcant prognostic information in that relationship.
Furthermore, utility of 6-MWT as a marker of functional
status, morbidity, or other parameters has not been fully
explored. One retrospective study evaluating pretransplant
6-MWT performance of 130 patients concluded that the
distance covered was not useful as a marker to predict long-
term mortality in the posttransplant setting, as there was no
statistically signiﬁcant diﬀerence in survival curves based on
distance covered.
The 6-MWT is the most commonly used test for the
assessment of exercise and functional capacity, in part, no
doubt, due to the relative ease of administration. Addition-
ally, when compared to other measures of exercise capacity,
such as the 2-minute walk test, 12-minute walk test, self-
paced walk test, and shuttle walk test, the 6-MWT has
been established as well tolerated by patients and more
reﬂective of the activities of daily living [23]. However,Pulmonary Medicine 3
performance on a 6-MWT is not a reliable surrogate marker
ofmoretraditionalindicesofexercisecapacity—suchascycle
ergometry—though some studies have demonstrated utility
in some populations, such as COPD patients, who may not
be able to complete a CPET [24]. The 6-MWT has several
limitation [25]; for instance, it does not determine peak
oxygen uptake, and therefore an objective determination
of functional capacity and impairment cannot be made,
nor can the relative contributing factors that limit exercise
be elicited. In addition, the 6-MWT is limited by the so-
called “ceiling eﬀect” leaving patients who walked most at
baseline with little room for improvement without jogging
[26]. Moreover, there is a learning eﬀect when the 6-
MWT is administered repeatedly which occurs after the
ﬁrst administration and is maintained for 2 months and
occurs to a lesser extent with repeated administration [27].
Though in some clinical situations, the 6-MWT may clearly
provide helpful information in terms of functional status.
Given these limitations, the American Thoracic Society
(ATS)recommendationoutlinesthat6-MWTdatashouldbe
complementarytocardiopulmonaryexercisetesting,andnot
as u b s t i t u t e[ 28].
1.3. Cardiopulmonary Exercise Test (CPET). Guidelines re-
garding routine use of CPET pre- and post-transplant are
lacking, which reﬂects the absence of signiﬁcant data on
how to apply CPET results for optimization of timing of
transplant and predicting outcomes. Several studies from the
1990s, described below, have attempted to evaluate the role
of CPET in the lung transplant population. Most of these
studies (Table 2), however, are limited by small sample sizes,
evaluation of a speciﬁc respiratory pathology, as well as type
oftransplant(i.e.,single versusbilateralsequential).Thelack
of generalizability thus makes real-life application of these
study results in the clinical setting challenging.
1.3.1. In the Evaluation Phase for Lung Transplantation.
The utility of CPET has been evaluated in some speciﬁc
lung diseases but has not been evaluated on a broader
scale in a heterogeneous population. The clinical course
of disease progression can be diﬃcult to predict for many
chronic respiratory disorders, thereby making selection of
the optimal time of transplantation challenging.
(i) Interstitial Lung Disease (ILD). In ILD, there are conﬂict-
ing reports on the value of diﬀerent variables on CPET in
predicting mortality [10]. In one study of 117 patients with
IPF, a peak VO2 of less than 8.3mL/min/kg was associated
with an increased risk of subsequent mortality. On adjusted
multivariate analysis, VO2 max threshold was a more robust
predictorofsurvivalthanrestingPaO2 ordesaturationbelow
88% during 6-MWT [10]. However, in this study only 8
patients (6.83%) were below the threshold, but about 46% of
patients died. This strongly suggests that while the threshold
is informative, it does not help to predict a large part of
the mortality in IPF. Surprisingly, not all patients below the
threshold peak VO2 desaturated below 88% during the 6-
MWT, suggesting perhaps that “self pace” allowed patients
Table 2: CPET indicators that correlate with outcome.
Disease CPET outcome variable Reference
Idiopathic
pulmonary ﬁbrosis
VO2 ≤ 8.3mL/min/kg [10]
PaO2 slope ≤− 60mmHg/L/min [11]
Chronic
obstructive
pulmonary disease
VO2 max (<15mL/min/kg) [12]
VO2 max < 60% predicted [12]
VO2 max [13]
PaO2 slope ≤− 80mmHg/L/min [14]
Pulmonary
vascular disease
peak SBP ≤ 120mm or less and [15]
peak VO2 ≤ 10.4mL/kg/min
Cystic ﬁbrosis
VO2 max,VE/VO2, peak work [16]
VO2 of 45mL/min/kg [17]
to trade oxygen saturation for distance walked and perhaps
the importance of the composite score distance-saturation
product as a more accurate predictor of survival [29].
In a retrospective study of 41 patients, Miki, et al.,
found that PaO2-slope (ΔPaO2/ΔVO2) was the most useful
predictor of survival, independent of age [11]. A PaO2-
slope equal or less than −60mmHg/L/min was predictive of
decreased survival with a median survival of 1.6 versus 4.5
years.TheimportantaspectsofthispaperareﬁrstthatPaO2-
slope could not be correlated to diﬀusion capacity of carbon
monoxide (DLCO) at rest; second that it suggests potential
beneﬁts for pulmonary rehabilitation in IPF (supplemental
O2, suppressing shallow breathing, etc..). Pulmonary reha-
bilitation was subsequently shown to improve 6-MWD and
fatigue in subjects with IPF [30].
(ii) Chronic Obstructive Pulmonary Disease (COPD). Pul-
monary function tests (PFTs) can correlate poorly with exer-
cise performance on CPET for COPD patients, with some
patients exceeding exercise limits despite severe impairment
on PFTs and others with more surprising limitations than
suggested by PFTs. Ortega et al. [12], in their study of 78
stable patients with COPD, showed that the deﬁnition of
impairment would vary greatly whether an absolute cut-
oﬀ value for VO2 max is used (15mL/kg/min) or a percent
predicted VO2 max less than 60%. The absolute number
has better speciﬁcity (79.5 versus 66.6), and the percent
predicted has better sensitivity (64.1% versus 41%) [12].
In a prospective study of 150 male patients with COPD,
a multivariate analysis showed that peak VO2 expressed as
a continuous variable negatively correlated with survival
(0.994; 0.992–0.996 P<0.0001). Age was positively corre-
lated with outcome albeit to a lesser degree than VO2 max
(1.077; 1.010–1.149 P = 0.024) [13]. However, this study
excluded patients with comorbidities, which are known to
play a key role in the outcome of patients with COPD. The
samegroupthatexaminedPaO2-slopeinIPF[11]c onduct ed
a retrospective study of 195 patients and found that PaO2-
slope correlated to survival more than PFT parameters [14].
A measurement of functional capacity, beyond resting PFTs
and 6-MWT, clearly adds valuable information to the care of
patientswithCOPD,allowingimprovedprognosticationand
perhaps better timing for transplant listing.4 Pulmonary Medicine
(iii) Pulmonary Vascular Disease. In pulmonary hyperten-
sion, CPET may be helpful to risk stratify patients into high-
risk versus medium- or low-risk [15]. Speciﬁcally, in one
study of 86 patients with primary pulmonary hypertension,
a peak SBP of 120mm or less and a peak VO2 equal to or
lessthan10.4mL/kg/minhavebeenestablishedasapowerful
predictor of survival threshold. Use of exercise data such as
SBP and peak VO2 adds additional prognostic information
regarding overall survival outcomes, above resting hemody-
namicssuchasrightheartcatheterization,orimagingsuchas
echocardiogram.Eventherapydidnotpredictsurvivalinthis
series,stronglysuggestingakeyroleforCPETinthemanage-
mentofpatientswithpulmonaryvasculardisease.Inarecent
review Arena et al. described potential roles for CPET in
diagnosed and undiagnosed pulmonary hypertension [31].
Unfortunately, most of the studies included involved small
cohorts. Nevertheless, these small studies have consistently
observed a relationship between peak VO2, VE/VCO2 slope,
and PETCO2 and survival [31].
(iv) Cystic Fibrosis. Data suggest that CPET may predict
mortality in patients with cystic ﬁbrosis. Speciﬁcally, VO2
max, VE/VO2, and peak work were found to be signiﬁcant
predictors of mortality in a 5-year study of 92 adult patients
with cystic ﬁbrosis however FEV1 values appeared to be a
better predictor of mortality than peak VO2 [16].
In striking contrast, an earlier prospective study of
109 patients with cystic ﬁbrosis found that peak VO2 was
a signiﬁcant predictor of mortality, without independent
contribution of FEV1. Those with higher levels of aerobic
ﬁtness were more than three times likely to survive as
compared with those patients with lower levels of ﬁtness,
even after adjustment for other risk factors [32]. It remains
therefore unclear whether aerobic conditioning or resting
lung function is the biggest predictors of outcome in cystic
ﬁbrosis. Recent evidence suggesting that muscle function is
intrinsically abnormal in cystic ﬁbrosis may perhaps be the
link to explain that apparent contradiction [33].
Inoneseriesoftwenty-eightpediatricpatientswithcystic
ﬁbrosis,rateofdeclineinpeakVO2 andpeakVO2 oflessthan
32mL/min/kg was associated with increased mortality; peak
VO2 of45mL/min/kgappearedtobeassociatedwithsurvival
[17].
1.3.2. In Posttransplant. In the early 1990s, CPET per-
formance was evaluated in patients who had undergone
single and bilateral lung transplantation to evaluate peak
VO2 [34]. Despite resolution of pretransplant respiratory
symptoms and essentially normal pulmonary function in the
six bilateral lung transplant recipients—with mild restrictive
abnormalities seen in the six patients with single lung
transplants—the maximum VO2 was markedly reduced
one year after transplant. In bilateral lung recipients, VO2
maximum was 48.5% of predicted and only 44.2% predicted
in single lung recipients. All subjects in this series had
signiﬁcant respiratory reserve, indicating that there was no
evidence of ventilatory limitation to exercise in either group.
Results of this study have been conﬁrmed by subsequent
studies,oneofwhichfurtherdemonstratedthatCPETresults
were unchanged at 2 years after transplant in a cohort of 13
subjects, [35] suggesting that additional improvement does
not occur. The peak VO2 has been reported at 6 months,
with decreases between 9 and 12 months after transplant in
a group of eight bilateral transplant recipients as compared
to controls [36]. However, other studies suggest that peak
VO2 m a yb ea t1 2o re v e n2 4m o n t h s[ 37]. In bilateral
lung recipients, peak VO2 h a sb e e nr e p o r t e da sl o wa s
31% of predicted, [38] and as high as 60% [39]. Heart
rate and minute ventilation did not appear to be limiting
exercise [40]. Interestingly, gains in VO2, typically a doubling
to about 50% predicted VO2, may not be uniform across
underlying disease pathologies. One series of 153 subjects
evaluated prior to and following transplantation suggested
that the most beneﬁt was derived in patients with COPD,
emphysema, or alpha-1-antitrypsin, while patients who had
interstitial lung disease may have more modest improve-
ments[41].Thismayreﬂectdiﬀerencesinpretransplantlevel
of functioning however, the absolute VO2 after transplant
again appeared fairly ﬁxed after transplant at 50% predicted
VO2, regardless of pretransplant capacity. This same series
also failed to ﬁnd a primary pulmonary or cardiac limit to
exercise tolerance, with leg fatigue cited as overwhelmingly
as reason for termination of exercise. CPET may therefore
be useful in identifying causes of poor exercise tolerance in
subjects following lung transplant despite improvement of
PFT indices.
(i) Anemia. Anemia is common subsequent to transplanta-
tion of solid organs, with much of the data coming from the
renaltransplantpopulation.Despitepreexistingrenaldisease
in some patients and medication eﬀects on renal function,
posttransplantation anemia does not appear to be solely
mediated by renal dysfunction [42]. Losses during surgery,
medication eﬀects, immune-mediated factors, and diﬀerent
forms of hemolysis can all additionally contribute [43].
Several studies have shown that the percentage drop in VO2
max is 2/3 of the percentage drop in hemoglobin [44, 45].
The eﬀect of anemia, even mild anemia, may therefore be
profound when considered in conjunction with conditions
(discussed below) that might aﬀect tissue oxygen extraction.
Understanding the eﬀects of anemia on exercise capacity
is important, since transfusion guidelines are increasingly
stringent [46], and so other causes of declining functional
status in the presence of stable PFTs can be explored.
(ii) Chronic Muscle Deconditioning and Skeletal Muscle
Abnormalities. Long-term pretransplant debilitation has
been felt to play a role in posttransplant exercise perfor-
mance. However, even in the highest functioning pretrans-
plant group, after transplant, peak VO2 reﬂects pretransplant
performance in the 153 patients followed by Bartels prior to
and subsequent to transplantation [41]. Underlying disease
state does not appear to play a role in absolute peak
VO2 achieved in another series of fourteen single and
eleven bilateral lung transplant recipients [47]. SubgroupsPulmonary Medicine 5
of patients, particularly those with COPD, showed greater
improvementsinVO2 maxthanthosepatientswithIPF[41].
Despite the younger age of patients with cystic ﬁbrosis, age
does not appear to play a role in posttransplant peak VO2
[41]. This may reﬂect skeletal muscle abnormalities inherent
to CF patients, rather than a posttransplant eﬀect [48].
Suggestingthattheremaybeotherfactorsatplayinother
populations, Miyoshi’s study following six single and six
bilaterallungtransplantrecipientssuggestedthatpeakVO2 is
not signiﬁcantly diﬀerent after lung transplant as compared
to heart-lung recipients [34]. Indeed, consistent ﬁndings
clearly show that in posttransplant patients, peak VO2 is not
limited by ventilatory reserve, but instead, systemic oxygen
extraction is abnormal [49, 50]. Speciﬁcally, peak cardiac
output is normal, as much as 89% of predicted; there is
even evidence of beneﬁcial right heart remodeling seen after
bilateral lung transplantation based on a prospective study
following twenty subjects before and after transplantation
[37]. Despite this, however, arterial-mixed venous oxygen
content diﬀerence at peak exercise was only half of expected,
primarily due to inability of venous oxygen saturation to
decline normally.
In one series comparing exercise capacity of nine lung
transplant recipients with that of eight healthy volunteers,
ventilation, oxygen saturation, and mild anemia did not
appear to account for decreased peak VO2 as compared
to healthy volunteers. Instead, quadriceps muscle pH and
phosphorylation potential appeared to be reduced following
transplant, suggesting that abnormalities of skeletal muscle
oxidative capacity may be playing a role in decreased peak
VO2 after transplant [51]. Indeed, another study of twenty-
ﬁve subjects conﬁrmed a correlation between quadriceps
muscle force after transplant and exercise capacity [52].
The importance of posttransplant exercise and pulmonary
rehabilitation cannot be overstated, with multiple studies
showing positive eﬀects of rehabilitation on skeletal muscle
function and respiratory status, immediately after transplant
and in long-term survivors of lung transplant, without clear
beneﬁt for inpatient or outpatient rehabilitation [53–55].
(iii) Medications. Proximal myopathy due to corticos-
teroids and peripheral skeletal muscle abnormalities due
to cyclosporine have all been proposed likely contributing
factors to reduced exercise capacity [56]. In particular, even
a short course of 5 days of corticosteroids, as used for
acute rejection, may have profound eﬀects on respiratory
and skeletal muscle, with up to 45% of patients developing
acute generalized weakness as measured in one series of
thirteen subjects after lung transplantation [57]. Another
study evaluating muscle size and strength in six COPD
patients compared to six patients who had undergone single-
lung transplantation for COPD found that despite similar
strength and muscle size, muscle endurance was lower
in the transplant population, pointing towards a possible
eﬀect of immunosuppressant medications, as suggested by
animal data [58, 59]. The calcineurin signaling pathway
may play a role in signaling transition from fast-to-slow
skeletal muscle ﬁber-type transition [60]. Inhibition of this
pathway, therefore, could have important implications in
terms of peak work and exercise endurance in the post-
transplant setting. This is of important clinical implications,
particularly in patients whose lung function improves after
transplantbuttheirexercisetolerancedoesnotcorrelatewith
the improvement in lung function.
(iv) Eﬀects of Native Lung in COPD. CPET has also been
evaluated in patients who have undergone single lung
transplantation for COPD [61]. VO2 max in six single
lung recipients with underlying COPD was similar to that
of six single lung recipients with underlying IPF, without
evidence of ventilatory limitations to exercise. These ﬁndings
alleviate concerns over the hyperinﬂated native lung causing
decreased tidal volume, leading to ventilation perfusion
mismatch and impaired gas exchange. This is of critical
importance, since it should alleviate concerns over single
lung transplant in subjects with COPD [62] and should lead
clinicians to focus on other causes of lack of symptomatic
improvement of subjects with COPD following lung trans-
plant.
2. Summary
There clearly is a need for further prospective systematic
investigation of the role of CPET in the pre- and post- lung
transplant period. The above ﬁndings suggest that CPET
may provide useful information prior to transplantation
in various disease states, including risk stratiﬁcation and
prediction of mortality, in some cases beyond that of
pulmonary function tests and the 6-MWT. Additionally,
usage of CPET after transplant has repeatedly demonstrated
that despite improvement in lung function, the primary
limitation to exercise appears to be at the level of oxygen
extraction. If these contributing factors are better elucidated,
further improvements in outcomes may occur, either by
further optimizing factors in pretransplant setting or better
stratifying risk after transplant.
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